John Garvey, a Foley Private Equity & Venture Capital Partner, moderated this session with panelists Josh Hamermesh of Molecular Insight Pharmaceuticals, Inc. and Matt Karlyn of Foley. They addressed in-licensing technology, specifically how to identify potential profit opportunities; approaching potential business partners, pre-transaction due diligence; negotiating with the licensor; and integration of the in-licensed technology into the company business operations.
Related Insights
17 April 2025
Preparing for a “Common-Sense” FAR: What Federal Contractors Need to Know About the Trump Administration’s Plans to Streamline the Federal Acquisition Regulation
In a new Executive Order issued on April 15, 2025 titled, “Restoring Common Sense to Federal Procurement,” President Trump has directed his Administration to make major revisions to the Federal Acquisition Regulation—the voluminous set of rules governing the U.S. Government’s acquisition of products and services—with the stated purpose of making the federal procurement process more “agile, effective, and efficient.”
16 April 2025
Video
Ten Minute Interview: Bridging M&A Valuation Gaps with Earnouts and Rollovers
Brian Lucareli, director of Foley Private Client Services (PCS) and co-chair of the Family Offices group, sits down with Arthur Vorbrodt, senior counsel and member of Foley’s Transactions group, for a 10-minute interview to discuss bridging M&A valuation gaps with earnouts and rollovers.
15 April 2025
Foley Viewpoints
Pricing Under Pressure: Prepare for Enhanced Antitrust Scrutiny amid Tariff Uncertainty
In an era of increased tariff pressures, U.S. antitrust enforcers have signaled that they remain vigilant for attempts by businesses to exploit the situation through anticompetitive conduct, especially in sectors already strained by supply shocks, volatile input costs, and shifting demand patterns.